This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: The Innovative Contributions of Juergen Thun in Pharmaceutical Chemistry
Introduction
Juergen Thun is an esteemed inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his unique innovations. With a focus on novel compounds, his work aims to enhance therapeutic options in medicine.
Latest Patents
Juergen Thun holds a notable patent entitled "Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making." This innovative patent describes a process for preparing 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one. The compounds developed through this process are considered pharmaceutically active, providing potential new avenues for treatment.
Career Highlights
Juergen Thun works at Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His role focuses on research and development, harnessing his expertise to drive innovations that aim to improve patient outcomes. His patent showcases his advanced knowledge and commitment to developing effective pharmaceutical solutions.
Collaborations
Throughout his career, Juergen has likely collaborated with various teams in Hoffmann-La Roche Inc. Working alongside fellow researchers and professionals, Juergen combines his expertise with others to push the boundaries of pharmaceutical innovation. Such collaborations may enhance the potential of his patented compounds, bringing them closer to viable clinical applications.
Conclusion
Juergen Thun exemplifies the spirit of innovation in the field of pharmaceutical chemistry. His patent highlights his significant contributions to creating new therapeutic options. As he continues his work at Hoffmann-La Roche Inc., his research may pave the way for future advancements in medicine, benefiting countless patients worldwide.
